Kaneda Ruri, Toyota Minoru, Yamashita Yoshihiro, Koinuma Koji, Choi Young Lim, Ota Jun, Kisanuki Hiroyuki, Ishikawa Madoka, Takada Shuji, Shimada Kazuyuki, Mano Hiroyuki
Division of Functional Genomics, Jichi Medical School, 3311-1 Yakushiji, Kawachigun, Tochigi 329-0498, Japan.
Genes Cells. 2004 Dec;9(12):1167-74. doi: 10.1111/j.1365-2443.2004.00804.x.
Although acetylation-deacetylation of histones contributes to regulation of gene expression, few methods have been available to determine the whole-genome histone acetylation profile in specific cells or tissues. We have now developed a genome-wide screening method, differential chromatin scanning (DCS), to isolate genome fragments embedded in histones subject to differential acetylation. This DCS screening was applied to a human gastric cancer cell line incubated with or without an inhibitor of histone deacetylase (HDAC) activity, resulting in the rapid identification of more than 250 genome fragments. Interestingly, a number of cancer-related genes were revealed to be the targets of HDAC in the cancer cells, including those for tumour protein 73 and cell division cycle 34. Such differential acetylation of histone was also shown to be linked to the regulation of transcriptional activity of the corresponding genes. Among the isolated genome fragments, 94% (32/34) of them were confirmed to be bound to differentially acetylated histones, and the genes corresponding to 78% (7/9) of them exhibited differential transcriptional activity consistent with the level of histone acetylation. With its high fidelity, the DCS method should open a possibility to rapidly compare the genome-wide histone acetylation profiles and to provide novel insights into molecular carcinogenesis.
尽管组蛋白的乙酰化-去乙酰化作用有助于基因表达的调控,但此前几乎没有方法可用于确定特定细胞或组织中的全基因组组蛋白乙酰化图谱。我们现已开发出一种全基因组筛选方法——差异染色质扫描(DCS),用于分离嵌入具有不同乙酰化水平组蛋白中的基因组片段。将这种DCS筛选应用于在有或没有组蛋白去乙酰化酶(HDAC)活性抑制剂的情况下培养的人胃癌细胞系,结果快速鉴定出250多个基因组片段。有趣的是,许多癌症相关基因被发现是癌细胞中HDAC的作用靶点,包括肿瘤蛋白73和细胞分裂周期34的相关基因。组蛋白的这种差异乙酰化还显示与相应基因转录活性的调控有关。在分离出的基因组片段中,94%(32/34)被证实与差异乙酰化的组蛋白结合,其中78%(7/9)的片段对应的基因表现出与组蛋白乙酰化水平一致的差异转录活性。凭借其高保真度,DCS方法应能为快速比较全基因组组蛋白乙酰化图谱以及深入了解分子致癌机制提供新的契机。